deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT06413095

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Pembrolizumab Alone and in Combination(s) With MK-0482 and MK-4830 Via Intratumoral Injection in Patients With Head and Neck Squamous Cell Carcinoma or Soft Tissue Sarcoma Prior to Planned Surgical Intervention

Sponsor: Merck Sharp & Dohme LLC

Updated 4 times since 2024 Last updated: May 8, 2024 Started: Jun 1, 2022 Primary completion: Jun 22, 2023 Completion: Jun 22, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Head and Neck Squamous Cell Carcinoma and Soft Tissue Sarcoma, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

4 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed EARLY_PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed EARLY_PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

    First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Presage Biosciences
Data source: Presage Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .